Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARA-31
2022-502417-28-01Phase 3Authorised
- Sponsor
- Biophytis
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Sarcopenia comparing BIO-101 with Placebo (2 arms). Primary endpoint: Time to onset of Major Mobility Disability (MMD). Planned start Aug 2025; status: authorised.
02
Drugs
20-hydroxyecdysone
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on 2022-502417-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502417-28-01.